A groundbreaking study from the UK has revealed a potential game-changer in the fight against advanced breast cancer. Researchers at the Institute of Cancer Research in London have developed a blood test that can predict how patients with advanced breast cancer will respond to targeted therapies. This innovative test analyzes circulating tumour DNA (ctDNA) in the blood, shedding light on the genetic changes associated with the tumour. Dr. Arun Kumar Goel, a renowned oncologist, explains the significance of this discovery and its implications for breast cancer treatment.
Breast cancer is a global concern, affecting millions of women worldwide. In 2022 alone, approximately 2.3 million women were diagnosed with breast cancer, and around 670,000 succumbed to the disease. In India, breast cancer has emerged as the most prevalent cancer among women, with a new diagnosis every few minutes. Early detection is crucial, as it significantly improves treatment outcomes and survival rates. However, despite the availability of screening methods, many women still ignore symptoms due to fear, stigma, or lack of awareness.
The study's findings, published in the Clinical Cancer Research journal, highlight a strong correlation between low levels of ctDNA at the start of treatment and a positive response to therapy. This association was consistent after four weeks, indicating that the test could predict treatment efficacy early on. Dr. Goel emphasizes that while low ctDNA levels suggest a probable cure, it does not guarantee long-term disease-free survival. Some tumours may shed minimal ctDNA, making the disease undetectable at a microscopic level or hidden in sanctuary sites like the brain.
The potential of ctDNA testing extends beyond treatment monitoring. Dr. Goel suggests that it can reduce the need for invasive biopsies in specific cases, such as tracking treatment success, identifying resistance mutations, or when obtaining tissue samples is challenging. However, he clarifies that ctDNA testing should not replace biopsies, as they remain essential for initial diagnosis, tumour grading, and detailed analysis by pathologists and immuno-histochemists.
This groundbreaking research opens up new avenues for personalized breast cancer treatment, offering hope for improved outcomes and quality of life for patients. As the medical community continues to explore these advancements, awareness and early detection remain vital in the battle against breast cancer.
